Smart drug

Nuzest-USA's Clean Lean Protein Product Wins Award for Best Plant-Based Protein Powder Supplement of 2023

Retrieved on: 
Thursday, April 27, 2023
Health, COVID-19, Multiple sclerosis, USD, Dicarboxylic acid, Sale, Government, Sodium, Environment, Smart drug, Dietary supplement

NEW YORK, April 27, 2023 /PRNewswire/ -- Nuzest's emphasis on product quality and manufacturing integrity is not surprising given its unique family-based history. Founded in New Zealand in 2012 by Trevor Bolland, the corporation's products were first formulated to meet the needs of Bolland's daughter, Monique, who was diagnosed with multiple sclerosis when she was 22 years old. [See full press release.]

Key Points: 
  • Nuzest-USA's Clean Lean Protein product has received the Smart Drugs and Supplements award for the best plant-based protein powder supplement of 2023.
  • NEW YORK, April 27, 2023 /PRNewswire/ -- Nuzest's emphasis on product quality and manufacturing integrity is not surprising given its unique family-based history.
  • Nuzest is taking advantage of these trends by producing high-quality products that feature the best natural ingredients available.
  • The company has also built a reputation for developing methods to ensure that those ingredients are minimally processed and turned into a clean powder.

Smart Drugs & Pills Global Market Report 2022-2027: Increased Preference for Less Complex and Painful Diagnostic Examinations with Minimally Invasive Surgeries Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 4, 2022
Health, Pharmaceutical, USD, Research, COVID-19, Capsule endoscopy, Monitoring, Tisbury Great Pond Target Area, Smart drug, CAGR, Stomach, Midsayap Diagnostic Center and Hospital, Compound annual growth rate, Esophagus, Drug, Hospital, Application

The Global Smart Drugs & Pills Market size was estimated at USD 4,262.38 million in 2021, USD 5,124.99 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 20.41% to reach USD 12,993.72 million by 2027.

Key Points: 
  • The Global Smart Drugs & Pills Market size was estimated at USD 4,262.38 million in 2021, USD 5,124.99 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 20.41% to reach USD 12,993.72 million by 2027.
  • This research report categorizes the Smart Drugs & Pills to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Target Area, the market was studied across Esophagus, Large Intestine, Small Intestine, and Stomach.
  • Based on End User, the market was studied across Diagnostic Centers, Hospitals, and Research Institutes.
  • This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Smart Drugs & Pills market considering the current update on the conflict and its global response.

United States Smart Drugs & Pills Market Research Report 2022: Featuring Key Players Boston Scientific Corporation, GE Healthcare, Olympus Corporation & Others - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Pharmaceutical, Alternative Medicine, General Health, Health, Medical Devices, Hospitals, Vitamins, Supplements, Fitness & Nutrition, Acquisition, Decision-making, USD, Research, Strategic management, Market share analysis, Value, Mergers and acquisitions, Business Growth Fund, Customer support, COVID-19, Growth, Capsule endoscopy, Collaborative partnership, Monitoring, Smart drug, Tisbury Great Pond Target Area, Investment, CAGR, Weakness, Stomach, Use, News, Midsayap Diagnostic Center and Hospital, Compound annual growth rate, State, Esophagus, Gaps, Retail, Hospital, Application

The "Smart Drugs & Pills Market Research Report by Target Area (Esophagus, Large Intestine, and Small Intestine), End User, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smart Drugs & Pills Market Research Report by Target Area (Esophagus, Large Intestine, and Small Intestine), End User, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • This research report categorizes the Smart Drugs & Pills to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Target Area, the market was studied across Esophagus, Large Intestine, Small Intestine, and Stomach.
  • Based on End User, the market was studied across Diagnostic Centers, Hospitals, and Research Institutes.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Worldwide Smart Drugs & Pills Industry to 2026 - Rapid Development in the Smart Drugs and Pills Development Process Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Health, Pharmaceutical, Customer support, Strategic management, Value, Decision-making, Growth, Miniaturization, COVID-19, USD, Acquisition, Smart drug, CAGR, R, Market share analysis, Investment, Use, Business Growth Fund, Certification, Retail, Medical device, Dietary supplement, Birth control

What are the inhibiting factors and impact of COVID-19 shaping the Global Smart Drugs & Pills Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Smart Drugs & Pills Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Smart Drugs & Pills Market?
  • What is the competitive strategic window for opportunities in the Global Smart Drugs & Pills Market?
  • What modes and strategic moves are considered suitable for entering the Global Smart Drugs & Pills Market?

US Smart Drugs & Pills Market Research Report 2021-2026 Featuring Boston Scientific, Medtronic, CapsoVision, Olympus and More - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 16, 2021
Health, Pharmaceutical, Customer support, Strategic management, Investment, Value, Decision-making, Growth, Industry, COVID-19, Acquisition, Collaborative partnership, Smart drug, Research, Mergers and acquisitions, Market share analysis, Use, Consumer, Business Growth Fund, News, Retail

The analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.

Key Points: 
  • The analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.
  • The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

Emotional Intelligence Ventures Reg A Raise at $20M, Company Pursues Psylocibin Transdermal Delivery Research, Plans Nutraceutical Mushroom Supplements Launch

Retrieved on: 
Tuesday, October 19, 2021
Alternative Medicine, Health, Research, Pharmaceutical, Science, Biotechnology, Immune system, Emotional Intelligence, Seattle City Council, Weight loss, Goal, EI, Betterment, Medicalization, Airbnb, Fungus, Council, Research, Vidyard, Mental health, Time, CEO, Forward-looking statement, Forbes, Sleep, Smart drug, Cognition, Wefunder, Company

Ultimately, they are looking to raise a maximum of $49,999,999, and believe this is a completely doable goal.

Key Points: 
  • Ultimately, they are looking to raise a maximum of $49,999,999, and believe this is a completely doable goal.
  • The net proceeds of the offering will be used to accelerate the development and distribution of Eis medicinal and functional mushroom product lines.
  • David Nikzad, founder and CEO of Ei.Ventures notes, We are so committed to the nonaccredited investor, that we are pursuing a Regulation A offering.
  • As part of Eis dual track approach, they are planning to launch their line of functional mushroom MANA nutraceuticals in early 2022.